Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zsolt Hepp, Kathleen Wyne, Shivaji R. Manthena, Siting Wang & Ved Gossain. (2018) Adherence to thyroid hormone replacement therapy: a retrospective, claims database analysis. Current Medical Research and Opinion 34:9, pages 1673-1678.
Read now
Read now
Antoni Sicras-Mainar, Javier Rejas-Gutiérrez & Ruth Navarro-Artieda. (2015) Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain. ClinicoEconomics and Outcomes Research 7, pages 299-312.
Read now
Read now
Articles from other publishers (15)
Sabrina Giometto, Laura Baglietto, Marco Conte, Alfredo Vannacci, Marco Tuccori, Alessandro Mugelli, Rosa Gini & Ersilia Lucenteforte. (2021) Use of antiseizure medications and safety of branded versus generic formulations: A comparative study on Tuscan administrative databases. Epilepsy & Behavior 117, pages 107876.
Crossref
Crossref
R. Navarro-Artieda, J. Rejas-Gutiérrez, M. Pérez-Paramo & A. Sicras-Mainar. (2018) Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex. Neurología (English Edition) 33:3, pages 141-153.
Crossref
Crossref
R. Navarro-Artieda, J. Rejas-Gutiérrez, M. Pérez-Paramo & A. Sicras-Mainar. (2018) Efecto de la edad y el género sobre las consecuencias clínicas y económicas del tratamiento con especialidad farmacéutica de marca o genérica en pacientes con dolor neuropático periférico en práctica clínica habitual. Neurología 33:3, pages 141-153.
Crossref
Crossref
Patrick Kwan & André Palmini. (2017) Association between switching antiepileptic drug products and healthcare utilization: A systematic review. Epilepsy & Behavior 73, pages 166-172.
Crossref
Crossref
Michael D Privitera, Timothy E Welty, Barry E Gidal, Francisco J Diaz, Ron Krebill, Jerzy P Szaflarski, Barbara A Dworetzky, John R Pollard, Edmund J ElderJrJr, Wenlei Jiang, Xiaohui Jiang & Michel Berg. (2016) Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. The Lancet Neurology 15:4, pages 365-372.
Crossref
Crossref
Yasunari Mano, Shota Fukushima, Hisayuki Kuroda, Hiroyuki Ohshima, Yoshinori Kato, Kaori Ohuchi, Kayoko Maezawa, Yasuyuki Momose, Shunya Ikeda & Mariko Asahi. (2015) Adherence to changing from brand-name to generic atorvastatin in newly treated patients: a retrospective cohort study using health insurance claims. Journal of Pharmaceutical Health Care and Sciences 1:1.
Crossref
Crossref
A. O’Leary, C. Usher, M. Lynch, M. Hall, L. Hemeryk, S. Spillane, P. Gallagher & M. Barry. (2015) Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Research Notes 8:1.
Crossref
Crossref
Emilio Perucca. 2015. The Treatment of Epilepsy. The Treatment of Epilepsy
110
123
.
Valérie Piguet, Stéphanie D’Incau, Marie Besson, Jules Desmeules & Christine Cedraschi. (2015) Prescribing Generic Medication in Chronic Musculoskeletal Pain Patients: An Issue of Representations, Trust, and Experience in a Swiss Cohort. PLOS ONE 10:8, pages e0134661.
Crossref
Crossref
Jette Rathe, Morten Andersen, Dorte Ejg Jarb?l, Ren? dePont Christensen, Jesper Hallas & Jens S?ndergaard. (2015) Generic Switching and Non-Persistence among Medicine Users: A Combined Population-Based Questionnaire and Register Study. PLOS ONE 10:3, pages e0119688.
Crossref
Crossref
Zoltán Kaló, Anke-Peggy Holtorf, Rafael Alfonso-Cristancho, Jie Shen, Tamás Ágh, András Inotai & Diana Brixner. (2015) Need for Multicriteria Evaluation of Generic Drug Policies. Value in Health 18:2, pages 346-351.
Crossref
Crossref
Vangelis Karalis, Panos Macheras & Meir Bialer. (2013) Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations. CNS Drugs 28:1, pages 69-77.
Crossref
Crossref
Michelle Hottinger & Bryan A. Liang. (2021) Deficiencies of the FDA in Evaluating Generic Formulations: Addressing Narrow Therapeutic Index Drugs. American Journal of Law & Medicine 38:4, pages 667-689.
Crossref
Crossref
O. Ström & E. Landfeldt. (2011) The association between automatic generic substitution and treatment persistence with oral bisphosphonates. Osteoporosis International 23:8, pages 2201-2209.
Crossref
Crossref
Paul Boon, Sebastiaan Engelborghs, Henri Hauman, An Jansen, Lieven Lagae, Benjamin Legros, Michel Ossemann, Bernard Sadzot, Katrien Smets, Etienne Urbain & Kenou van Rijckevorsel. (2012) Recommendations for the treatment of epilepsy in adult patients in general practice in Belgium: an update. Acta Neurologica Belgica 112:2, pages 119-131.
Crossref
Crossref